Literature DB >> 11549530

Inhaled corticosteroids, combined with long-acting beta(2)-agonists, improve the perception of bronchoconstriction in asthma.

I D Bijl-Hofland1, S G Cloosterman, H T Folgering, F J van den Elshout, C van Weel, C P van Schayck.   

Abstract

The relationship between asthma medication and the perception of asthma symptoms is of interest for daily practice. Poor perception of asthma symptoms might influence patients' health care behavior and subsequently might lead to undertreatment and deterioration of their disease. This study investigated the influence of the chronic use of short-acting and long-acting beta(2)-agonists, compared with the additional use of inhaled corticosteroids on the perception of histamine-induced bronchoconstriction. Patients with asthma (33 male and 31 female, mean age 35 +/- 11 yr, FEV(1) 87 +/- 14% of the reference value, PC(20) geometric mean 1.08 mg/ml (95% CI: 0.76-1.52) were selected and randomly allocated to the use of either a short-acting beta(2)-agonists (salbutamol, n = 22) or a long-acting beta(2)-agonists (formoterol, n = 22) or placebo (n = 20), which has been used for 12 wk. This medication treatment was repeated exactly 1 yr later, with patients receiving the same medication plus an inhaled corticosteroid. Perception of histamine-induced bronchoconstriction was measured at the start of each treatment period and every 4 wk thereafter. Subjects quantified their sensation of respiratory discomfort during the challenge tests on a modified Borg scale. The perceptive "sensitivity" for changes in FEV(1) was analyzed by the linear regression slope (alpha) "Borg versus percentage fall in FEV(1)." The "absolute perceptual magnitude" was determined by the perception score at the 20% fall in FEV(1) (PS(20)). The additional use of inhaled corticosteroids during the second year resulted in an improved perception of histamine-induced bronchoconstriction (slope alpha) compared with the first year for only the long-acting beta(2)-agonists group (p value 0.036). This improvement was not observed for the "absolute perceptual magnitude" (PS(20)). The additional use of inhaled corticosteroids during chronic use of long-acting beta(2)-agonists improves the perceptive "sensitivity" for changes in FEV(1) during histamine-induced bronchoconstriction, which was not observed for short-acting bronchodilators. This result might indicate that the positive effects on perception of airway obstruction might be another reason (besides the beneficial effects on the clinical condition) for prescribing a combination of long-acting beta(2)-agonists and inhaled steroids.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11549530     DOI: 10.1164/ajrccm.164.5.9910103

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  13 in total

1.  Perception of airway narrowing during reduction of inhaled corticosteroids and asthma exacerbation.

Authors:  C M Salome; J D Leuppi; R Freed; G B Marks
Journal:  Thorax       Date:  2003-12       Impact factor: 9.139

Review 2.  Addition of long-acting beta2-agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthma.

Authors:  Francine M Ducharme; Muireann Ni Chroinin; Ilana Greenstone; Toby J Lasserson
Journal:  Cochrane Database Syst Rev       Date:  2010-04-14

Review 3.  Addition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children.

Authors:  Francine M Ducharme; Muireann Ni Chroinin; Ilana Greenstone; Toby J Lasserson
Journal:  Cochrane Database Syst Rev       Date:  2010-05-12

Review 4.  Serious adverse events and death associated with treatment using long-acting beta-agonists.

Authors:  Fernando D Martinez
Journal:  Clin Rev Allergy Immunol       Date:  2006 Oct-Dec       Impact factor: 8.667

Review 5.  Perception of airway obstruction and airway inflammation in asthma: a review.

Authors:  Elisabetta Rosi; Loredana Stendardi; Barbara Binazzi; Giorgio Scano
Journal:  Lung       Date:  2006 Sep-Oct       Impact factor: 2.584

Review 6.  Addition of inhaled long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults and children.

Authors:  Muireann Ni Chroinin; Ilana Greenstone; Toby J Lasserson; Francine M Ducharme
Journal:  Cochrane Database Syst Rev       Date:  2009-10-07

Review 7.  Regular treatment with salmeterol for chronic asthma: serious adverse events.

Authors:  Christopher J Cates; Matthew J Cates
Journal:  Cochrane Database Syst Rev       Date:  2008-07-16

Review 8.  Regular treatment with formoterol for chronic asthma: serious adverse events.

Authors:  Christopher J Cates; Matthew J Cates
Journal:  Cochrane Database Syst Rev       Date:  2012-04-18

Review 9.  Regular treatment with formoterol versus regular treatment with salmeterol for chronic asthma: serious adverse events.

Authors:  Christopher J Cates; Toby J Lasserson
Journal:  Cochrane Database Syst Rev       Date:  2012-03-14

Review 10.  Stopping long-acting beta2-agonists (LABA) for children with asthma well controlled on LABA and inhaled corticosteroids.

Authors:  Kayleigh M Kew; Sean Beggs; Shaleen Ahmad
Journal:  Cochrane Database Syst Rev       Date:  2015-05-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.